SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Inflammation Research

• Publication date

  2011-01-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00011-010-0306-1PMID 21279417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment.

  2010cited by this paper
• Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.

  2010cited by this paper
• The bile acid sensor FXR regulates insulin transcription and secretion.

  2010cited by this paper
• Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.

  2009cited by this paper
• The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity1

  2009cited by this paper
• The niche of stellate cells within rat liver

  2009cited by this paper
• Antiatherosclerotic effect of farnesoid X receptor.

  2009cited by this paper
• Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.

  2009cited by this paper
• Hepatic myofibroblasts: a heterogeneous population of multifunctional cells in liver fibrogenesis.

  2009cited by this paper
• Monocytes and macrophages as cellular targets in liver fibrosis.

  2009cited by this paper
• Molecular pathogenesis of liver fibrosis.

  2009cited by this paper
• FXR an emerging therapeutic target for the treatment of atherosclerosis

  2009cited by this paper
• A mechanism for the anti-fibrogenic effects of the pregnane X receptor (PXR) in the liver: inhibition of NF-kappaB?

  2008cited by this paper
• Starring stellate cells in liver immunology.

  2008cited by this paper
• A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells.

  2008cited by this paper
• Immune interactions in hepatic fibrosis.

  2008cited by this paper
• Nuclear receptors in human immune cells: expression and correlations.

  2007cited by this paper
• Targeting farnesoid X receptor for liver and metabolic disorders.

  2007cited by this paper
• Combinatorial roles of nuclear receptors in inflammation and immunity

  2006cited by this paper
• Benefit of farnesoid X receptor inhibition in obstructive cholestasis.

  2006cited by this paper
• Farnesoid X receptor is essential for normal glucose homeostasis.

  2006cited by this paper
• The impact of pregnane X receptor activation on liver fibrosis.

  2006cited by this paper
• Pregnane X Receptor Is a Target of Farnesoid X Receptor*

  2006cited by this paper
• The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo

  2006influential reference
• The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

  2004cited by this paper
• Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation.

  2004cited by this paper
• LPS-mediated NFκB activation varies between activated human hepatic stellate cells from different donors

  2004cited by this paper
• Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.

  2003cited by this paper
• LPS-mediated NFkappaB activation varies between activated human hepatic stellate cells from different donors.

  2003cited by this paper
• Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells.

  2003cited by this paper
• Nuclear receptors and the control of metabolism.

  2003cited by this paper
• Toll‐Like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells

  2003cited by this paper
• Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.

  2002cited by this paper
• RNA interference is mediated by 21- and 22-nucleotide RNAs.

  2001cited by this paper
• Peroxisome Proliferator-activated Receptor γ Inhibits Transforming Growth Factor β-induced Connective Tissue Growth Factor Expression in Human Aortic Smooth Muscle Cells by Interfering with Smad3*

  2001cited by this paper
• Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation*

  2000cited by this paper
• Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells.

  2000cited by this paper
• A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.

  2000cited by this paper
• An Orphan Nuclear Hormone Receptor That Lacks a DNA Binding Domain and Heterodimerizes with Other Receptors

  1996cited by this paper

• Raffinose-metabolizing bacteria impair radiation-associated hematopoietic recovery via the bile acid/FXR/NF-κB signaling pathway

  2025cites this paper
• Bile acids and their receptors in hepatic immunity

  2025cites this paper
• Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis.

  2024cites this paper
• Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

  2024cites this paper
• Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets

  2024cites this paper
• Current and emerging strategies for the prevention of hepatocellular carcinoma

  2024influential citation
• Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion

  2024cites this paper
• The interaction of bile acids and gut inflammation influences the pathogenesis of inflammatory bowel disease

  2023cites this paper
• The role of peroxisome proliferator‐activated receptors in the regulation of bile acid metabolism

  2023cites this paper
• Mechanism for FXR to regulate bile acid and glycolipid metabolism to improve NAFLD

  2023cites this paper
• The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets

  2023cites this paper
• Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols.

  2023cites this paper
• Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling

  2022cites this paper
• Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation.

  2022cites this paper
• Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease

  2022cites this paper
• Liver macrophages and inflammation in physiology and physiopathology of non‐alcoholic fatty liver disease

  2021cites this paper
• Nuclear Receptors in Liver Fibrosis.

  2021cites this paper
• Bile Acids and FXR: Novel Targets for Liver Diseases

  2020cites this paper
• Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis.

  2020cites this paper
• A Villin-Driven Fxr Transgene Modulates Enterohepatic Bile Acid Homeostasis and Response to an n-6-Enriched High-Fat Diet

  2020cites this paper
• The small heterodimer partner inhibits activation of hepatic stellate cells via autophagy.

  2020cites this paper
• Obeticholic Acid Ameliorates Valproic Acid–Induced Hepatic Steatosis and Oxidative Stress

  2020cites this paper
• Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

  2019cites this paper
• n-6 Linoleic Acid Induces Epigenetics Alterations Associated with Colonic Inflammation and Cancer

  2019cites this paper
• Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

  2019cites this paper
• Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis

  2019cites this paper
• Update on FXR Biology: Promising Therapeutic Target?

  2018cites this paper
• Disruption of TFG&bgr;‐SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand

  2018cites this paper
• Regulation of non-alcoholic steatohepatitis and hepatic fibrosis development by the bile acid-FXR-FGF19 pathway

  2018cites this paper
• Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis

  2017cites this paper
• Small heterodimer partner (SHP) contributes to insulin resistance in cardiomyocytes.

  2017cites this paper
• Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1

  2017cites this paper
• Novel bile acid therapeutics for the treatment of chronic liver diseases

  2016cites this paper
• Fatty liver diseases, bile acids, and FXR

  2016cites this paper
• Emerging roles of orphan nuclear receptors in regulation of innate immunity

  2016influential citation
• Role of farnesoid X receptor in establishment of ontogeny of phase-I drug metabolizing enzyme genes in mouse liver

  2016cites this paper
• The orphan nuclear receptor small heterodimer partner is required for thiazolidinedione effects in leptin-deficient mice

  2015cites this paper
• Squalene targets pro- and anti-inflammatory mediators and pathways to modulate over-activation of neutrophils, monocytes and macrophages

  2015cites this paper
• The role of bile acids and farnesoid X receptor in ileal Crohn's disease

  2015cites this paper
• 3. Stellate cells

  2015cites this paper
• Hepatic PPARs: their role in liver physiology, fibrosis and treatment.

  2013cites this paper
• Cyclosporine A treated in vitro models induce cholestasis response through comparison of phenotype-directed gene expression analysis of in vivo Cyclosporine A-induced cholestasis.

  2013cites this paper
• FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents.

  2013cites this paper
• SUMOylation of PPARγ by Rosiglitazone Prevents LPS-Induced NCoR Degradation Mediating Down Regulation of Chemokines Expression in Renal Proximal Tubular Cells

  2013cites this paper
• Farnesoid X receptor in the study of fibrosis and its treatments

  2013cites this paper
• Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside

  2012cites this paper
• FXR ligands protect against hepatocellular inflammation via SOCS3 induction.

  2012cites this paper
• Modification in the side chain of solomonsterol A: discovery of cholestan disulfate as a potent pregnane-X-receptor agonist.

  2012cites this paper
• Liver Fibrogenesis in Non-Alcoholic Steatohepatitis

  2012cites this paper
• Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

  2011cites this paper
• Nuclear Receptor Variants in Liver Disease

  2011cites this paper